Larvol Delta - A-Study-to-Evaluate-the-Safety-Tolerability-and-Efficacy-of-Pumitamig-Alone-or-in-Combination-With-Other-Agents-in-Participants-With-Advanced-Renal-Cell-Carcinoma-RCC-ROSETTA-RCC208

Yervoy (ipilimumab) - BMS

pumitamig (BNT327) - BioNTech, BMS

casdatifan (AB521) - Arcus Biosciences

Cabometyx (cabozantinib tablet) - Exelixis

http://clinicaltrials.gov/ct2/show/NCT07293351

Aug 29, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next